Key Details
Price
$19.49Annual ROE
3.37%Beta
1.05Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 29, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
– ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – Kiniksa expects to remain cash flow positive on an annual basis –
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman and Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Liisa Bayko - Evercore ISI Paul Choi - Goldman Sachs Eva Fortea-Verdejo - Wells Fargo David Nierengarten - Wedbush Securities Anupam Rama - JPMorgan Operator Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call.
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.01.
– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life DisRPted ™ disease awareness campaign for recurrent pericarditis launched in partnership with NHL Hall of Famer, Henrik Lundqvist, and GRAMMY ® Award-winning singer-songwriter, Carly Pearce – – Kiniksa expects to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09.
– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations –
FAQ
- What is the ticker symbol for Kiniksa Pharmaceuticals?
- Does Kiniksa Pharmaceuticals pay dividends?
- What sector is Kiniksa Pharmaceuticals in?
- What industry is Kiniksa Pharmaceuticals in?
- What country is Kiniksa Pharmaceuticals based in?
- When did Kiniksa Pharmaceuticals go public?
- Is Kiniksa Pharmaceuticals in the S&P 500?
- Is Kiniksa Pharmaceuticals in the NASDAQ 100?
- Is Kiniksa Pharmaceuticals in the Dow Jones?
- When was Kiniksa Pharmaceuticals's last earnings report?
- When does Kiniksa Pharmaceuticals report earnings?
- Should I buy Kiniksa Pharmaceuticals stock now?